Treatment
Cell clinical trials
We’re tracking 5,545 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT06543381RecruitingPhase 1
Olutasidenib for IDH1-mutated blood cancers after transplant
This trial tests a drug called olutasidenib for people with certain blood cancers (AML, MDS, or CMML) that have a specific IDH1 gene change. The goal is to see if it can help prevent relapse after a donor stem cell transplant.
Duarte, CaliforniaAges 18 years+ - NCT06543576RecruitingPhase 1/Phase 2
Radiation and drug therapy for stage IVB cervical cancer
This trial tests combining external and internal radiation with chemotherapy and immunotherapy for stage IVB cervical cancer that has not been treated before. The goal is to see if this approach can help shrink tumors and improve outcomes.
Los Angeles, CaliforniaAges 18 years+ - NCT06545747RecruitingPhase 3
MRI-guided radiation for advanced lung cancer
This trial tests a new way of giving radiation therapy for advanced lung cancer that cannot be surgically removed. It uses MRI scans to guide and adjust the radiation dose, which may help target the tumor more precisely and reduce side effects.
GuangzhouAges 18–75 - NCT04098146Recruiting
Registry for jawbone reconstruction after jaw cancer and jaw bone death
This study collects real-world information from people undergoing jaw reconstruction after their jaw bone was damaged (from cancer and certain medicines). It may help improve future treatment planning by tracking surgical choices and outcomes.
Jacksonville, FloridaAges 18 years+ - NCT06526117RecruitingPhase 4
Stroke Prevention in Nigeria 2 Trial
This trial tests whether giving hydroxyurea (a medicine that helps prevent strokes) to children with sickle cell disease who have high-risk blood flow in their brains can stop strokes from happening. It's for kids in Nigeria who are at the peak age for stroke risk (5–12 years old).
KanoAges 5–12 - NCT06529822RecruitingPhase 1
Personalized cancer vaccine for solid tumors with residual disease
This trial tests a personalized cancer vaccine designed to help your immune system fight any remaining cancer cells after surgery. It is for people with certain solid tumors—like bladder, stomach, melanoma, or lung cancer—that show signs of disease through a blood test.
Orlando, FloridaAges 18 years+ - NCT06519487Enrolling by invitation
How social experiences affect immune cells
This study looks at how social experiences and background may influence immune cell activity. It could help understand why some groups have different health outcomes.
Baltimore, MarylandAges 18 years+ - NCT06516679RecruitingPhase 2
Customized treatment for infants with newly diagnosed leukemia
This trial tests a treatment plan that adjusts therapy based on each baby's risk level. It aims to improve outcomes for infants newly diagnosed with certain types of leukemia.
DaeguAges Up to 2 years - NCT06517017RecruitingPhase 2
Gentle combination therapy for frail myeloma patients
This study tests a combination of three drugs (isatuximab, dexamethasone, and lenalidomide) given at a slow, gentle pace for people with multiple myeloma who are considered very frail. The goal is to see if this gentler approach works well and is safe for those who may not tolerate stronger treatments.
Salt Lake City, UtahAges 18 years+ - NCT06517511RecruitingPhase 2
Selinexor plus R-CHOP for first-line treatment of TP53-mutated DLBCL
This trial tests adding selinexor to the standard R-CHOP chemotherapy for people with a specific type of diffuse large B-cell lymphoma (DLBCL) that has a TP53 mutation. The goal is to see if this combination works better as the first treatment.
Guangzhou, GuangdongAges 18–80 - NCT06518668Enrolling by invitationPhase 1
NKX019 cell therapy for lupus
This study tests a new therapy called NKX019, which uses specially engineered natural killer cells to target a protein on lupus cells. It is for people with moderate to severe lupus that has not responded to standard treatments, especially those with active kidney inflammation.
New York, New YorkAges 18–65 - NCT06529731RecruitingPhase 2
Interferon-Gamma and Donor Cells for Relapsed Leukemia After Transplant
This trial tests combining a protein called interferon-gamma with an infusion of donor white blood cells to treat AML or MDS that returned after a stem cell transplant. The goal is to see if this combination helps the donor cells attack the cancer more effectively.
St Louis, MissouriAges 18 years+ - NCT06523543Recruiting
Early fetal genetic test using placental cells
This study tests a new method to detect genetic information from a pregnancy as early as 7 weeks, using cells from the placenta. It may help identify certain genetic conditions earlier than standard tests.
Montpellier, FranceAges 18 years+ - NCT06522737RecruitingPhase 3
Duvelisib vs chemotherapy for relapsed T-cell lymphoma
This trial tests a new drug, duvelisib, against two standard chemotherapy drugs (gemcitabine or bendamustine) for people with T-cell lymphoma that has come back or not responded to treatment. Duvelisib is a targeted therapy that may work differently than chemotherapy.
GhentAges 18 years+ - NCT06514508RecruitingPhase 3
Stem cell collection with motixafortide and G-CSF for multiple myeloma
This trial tests a new drug, motixafortide, combined with a standard growth factor (G-CSF) to help collect stem cells for a transplant in people with multiple myeloma. It may be a good option if your myeloma is in remission and you have not had a stem cell transplant before.
Beijing, Beijing MunicipalityAges 18–78 - NCT06127303RecruitingPhase 2
Toripalimab plus cryoablation for lung cancer with limited progression
This trial tests a combination of an immunotherapy drug (toripalimab) and a freezing treatment (cryoablation) for people with advanced non-small cell lung cancer that has started to grow again in only a few spots after initial treatment. It aims to see if this approach can help control the cancer without switching to a completely new therapy.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05728658RecruitingPhase 1
Study of ICP-248 for relapsed or refractory B-cell cancers
This early-phase (Phase 1) study tests ICP-248 in people with certain B-cell cancers that have come back (relapsed) or did not respond to prior treatment (refractory). The goal is to learn the safest dose and whether it can help shrink or control the cancer.
Bengbu, AnhuiAges 18–80 - NCT06503146RecruitingPhase 2
New imaging tracer for detecting various cancers
This trial tests a new imaging agent, [18F]FAPI-74, which might help detect certain cancers more clearly. The scan looks for a protein called fibroblast activation protein (FAP) that is often found in tumors. If you have one of the listed cancers and are about to start treatment, this study could help doctors see where the cancer is and how it responds to therapy.
Bethesda, MarylandAges 18–120 - NCT06500273RecruitingPhase 2
Cema-cel for high-risk lymphoma after first treatment
This trial tests a new treatment called cema-cel for people with large B-cell lymphoma who are in remission after first-line therapy but still have tiny amounts of cancer detected by a sensitive blood test. The goal is to prevent the cancer from coming back.
Gilbert, ArizonaAges 18 years+ - NCT06262321RecruitingPhase 2
Chest Radiation for Advanced Lung Cancer at High Risk of Symptoms
This study tests whether giving radiation to tumors in the chest soon after starting systemic therapy can help prevent symptoms like pain, trouble breathing, or bleeding. It is for people with advanced non-small cell lung cancer that does not have certain gene changes and has high-risk tumors in the chest.
Rochester, New YorkAges 18 years+ - NCT06497530RecruitingPhase 2
Lurbinectedin with serplulimab for extensive-stage SCLC maintenance
This trial tests a combination of two drugs, lurbinectedin and serplulimab, as maintenance therapy after initial chemotherapy for people with extensive-stage small cell lung cancer (SCLC) that hasn't spread to the brain. The goal is to see if this approach helps keep the cancer from growing for longer.
Guangzhou, GuangdongAges 18 years+ - NCT06498973RecruitingPhase 1
Maintenance therapy after stem cell transplant for CD123-positive AML/MDS
This trial tests a combination of two drugs, tagraxofusp and azacitidine, given as maintenance therapy after a stem cell transplant. The goal is to prevent the leukemia or MDS from coming back in patients whose cancer cells carry a specific marker called CD123.
Duarte, CaliforniaAges 18–75 - NCT06500481RecruitingPhase 3
Proton vs standard radiation for cancer spread to brain/spine lining
This trial compares a newer type of radiation (proton therapy) to standard radiation for people whose breast or lung cancer has spread to the lining of the brain and spinal cord. It aims to see if proton therapy can better control the disease while causing fewer side effects.
Phoenix, ArizonaAges 18 years+ - NCT06510491RecruitingPhase 2
Epcoritamab for relapsed Waldenstrom macroglobulinemia
This trial tests epcoritamab, an immunotherapy that helps your immune system attack cancer cells, for people with Waldenstrom macroglobulinemia (WM) whose disease has gotten worse or who couldn't tolerate previous treatments. It's for those who've already tried a BTK inhibitor (like ibrutinib or zanubrutinib) and an anti-CD20 antibody (like rituximab).
Boston, MassachusettsAges 18 years+
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,545 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.